Background
Methods
Search strategy
Inclusion criteria and exclusion criteria
Inclusion criteria
Exclusion criteria
Assessment of study quality
Data extraction
Statistical analysis
Result
Search results
Characteristics of included studies
Author | Sample (n) | Mean age (year) | Intervention | Comparison | Duration (month) | Outcomes | Study | |||
---|---|---|---|---|---|---|---|---|---|---|
Country | Intervention | Comparison | Intervention | Comparison | ||||||
Beck 2008 [11] | USA | 39 | 38 | 63 | 63 | Sc denosumab injections (60 mg Q6M) | Oral alendronate 70 mg once weekly | 24 | 56 | RCTs |
Lewiecki 2007 [12] | USA | 319 | 47 | 62.3 | 62.8 | Sc denosumab injections (60 mg Q6M) | Oral alendronate 70 mg once weekly | 24 | 1 | RCTs |
McClung 2006 [13] | USA | 47 | 47 | 63.1 | 62.8 | Sc denosumab injections (60 mg Q6M) | Oral alendronate 70 mg once weekly | 12 | 123,467 | RCTs |
Brown 2009 [14] | Spain | 594 | 595 | 64.1 | 64.6 | Sc denosumab injections (60 mg Q6M) | Oral alendronate 70 mg once weekly | 12 | 1,234,567 | RCTs |
Kendler 2010 [15] | USA | 253 | 251 | 66.9 | 68.2 | Sc denosumab injections (60 mg Q6M) | Oral alendronate 70 mg once weekly | 12 | 234,567 | RCTs |
Freemantle 2012 [16] | UK | 126 | 124 | 65.1 | 65.3 | Sc denosumab injections (60 mg Q6M) | Oral alendronate 70 mg once weekly | 24 | 2345 | RCTs |
Kendler 2011 [17] | Canada | 253 | 251 | 66.9 | 68.2 | Sc denosumab injections (60 mg Q6M) | Oral alendronate 70 mg once weekly | 12 | 56 | RCTs |
Recknor 2013 [18] | USA | 417 | 416 | 67.2 | 66.2 | Sc denosumab injections (60 mg Q6M) | Oral ibandronate 150 mg once month | 12 | 12,346 | RCTs |
Roux 2014 [19] | France | 422 | 402 | 67.8 | 67.7 | Sc denosumab injections (60 mg Q6M) | Oral risedronate 150 mg once month | 12 | 123,456 | RCTs |
Miller 2016 [20] | USA | 320 | 320 | 65.9 | 66.1 | Sc denosumab injections (60 mg Q6M) | intravenous zoledronic acid 5 mg once year | 12 | 123,457 | RCTs |
Seeman 2010 [21] | Australia | 83 | 82 | 60.3 | 60.7 | Sc denosumab injections (60 mg Q6M) | oral alendronate 70 mg once weekly | 12 | 23 | RCTs |
Quality of the included RCTs
Results of meta-analysis
Risk of fracture
Subgroup | No. of included studies | RR (95% CI) | I2 (%) |
---|---|---|---|
Comparator treatment | |||
Alendronate | 3 | 1.10 (0.95, 1.23) | 12.3 |
Ibandronate | 1 | 1.08 (0.89, 1.16) | – |
Risedronate | 1 | 1.23 (0.75, 1.08) | – |
Zoledronic acid | 1 | 0.86 (0.74, 0.99) | – |
Population who had been prescribed a treatment for osteoporosis | |||
No (< 100% of participants) | 4 | 1.15 (0.67, 1.22) | 0.0 |
No (> 100% of participants) | 3 | 1.12 (0.85, 1.08) | 0.0 |
High or unclear risk of bias | |||
No | 2 | 1.09 (0.74, 1.26) | 0.0 |
Yes | 5 | 1.31 (0.89, 1.14) | 0.0 |